{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:36:21Z","timestamp":1760747781284,"version":"build-2065373602"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.ejca.2022.04.037","type":"journal-article","created":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T11:40:32Z","timestamp":1655120432000},"page":"10-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Bilateral diffuse uveal melanocytic proliferation (BDUMP) as ocular toxicity from durvalumab in advanced renal carcinoma"],"prefix":"10.1016","volume":"171","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8371-4601","authenticated-orcid":false,"given":"Luka","family":"Mihic G\u00f3ngora","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Santalla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6268-6672","authenticated-orcid":false,"given":"D\u00e9bora","family":"Contreras Toledo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4084-0501","authenticated-orcid":false,"given":"Tamara","family":"D\u00edaz Vico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio","family":"Esteban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.ejca.2022.04.037_bib1","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.ejca.2022.04.037_bib2","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ejca.2022.04.037_bib3","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.ejca.2022.04.037_bib4","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejca.2022.04.037_bib5","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/CCO.0000000000000296","article-title":"Ocular and orbital side-effects of checkpoint inhibitors: a review article","volume":"28","author":"Antoun","year":"2016","journal-title":"Curr Opin Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2022.04.037_bib6","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1136\/bjophthalmol-2020-316970","article-title":"Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience","volume":"105","author":"Fortes","year":"2021","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"10.1016\/j.ejca.2022.04.037_bib7","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1080\/09273948.2019.1583347","article-title":"Ocular adverse events following use of immune checkpoint inhibitors for metastatic malignancies","volume":"28","author":"Noble","year":"2020","journal-title":"Ocul Immunol Inflamm"},{"issue":"4","key":"10.1016\/j.ejca.2022.04.037_bib8","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1001\/archopht.1990.01070060075053","article-title":"Bilateral diffuse uveal melanocytic proliferation in patients with occult carcinoma","volume":"108","author":"Gass","year":"1990","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ejca.2022.04.037_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2014-204387","article-title":"Bilateral diffuse uveal melanocytic proliferation: a management dilemma","volume":"2014","author":"Alrashidi","year":"2014","journal-title":"BMJ Case Rep"},{"issue":"5","key":"10.1016\/j.ejca.2022.04.037_bib10","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/aos.13481","article-title":"Bilateral diffuse uveal melanocytic proliferation: case report and literature review","volume":"95","author":"Klemp","year":"2017","journal-title":"Acta Ophthalmol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922002775?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922002775?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:36:41Z","timestamp":1760733401000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922002775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":10,"alternative-id":["S0959804922002775"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.04.037","relation":{},"ISSN":["0959-8049"],"issn-type":[{"type":"print","value":"0959-8049"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bilateral diffuse uveal melanocytic proliferation (BDUMP) as ocular toxicity from durvalumab in advanced renal carcinoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.04.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}